Armata Pharmaceuticals, Inc. (ARMP)

[Theo]

Form 8-K for AMPLIPHI BIOSCIENCES CORP

"On September 27, 2016, we entered into an amendment (the "Amendment") to the Consulting Agreement, dated September 3, 2015 (the "Consulting Agreement"), between us and Wendy S. Johnson, our Interim Chief Operating Officer. In accordance with the Amendment, Ms. Johnson will continue to receive monthly consulting fees for the services provided to the Company during the consulting period. In addition, Ms. Johnson is eligible for an additional cash payment of $100,000 for contributions made during fiscal year 2016, with such payment subject to and payable upon the achievement of a specified clinical milestone by December 31, 2016. The term of the Consulting Agreement, as amended, will expire on December 31, 2016 unless extended by mutual written agreement of the parties."

Wonder what "clinical milestone" needs to be achieved? Seems pretty clear we'll be getting an update of some sort regardless...